Skip to content
Evigrade
CriticalErgot alkaloid, 5-HT1B/1D and alpha-adrenoceptor agonist×Selective 5-HT1B/1D serotonin receptor agonist

Updated · Methodology

Mechanism

Both drugs constrict blood vessels. Rizatriptan binds selectively to 5-HT1B and 5-HT1D serotonin receptors, and stimulation of these receptors can constrict cranial blood vessels (rizatriptan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Dihydroergotamine, an ergotamine derivative, binds to 5-HT1D receptors, and its main metabolite is as potent a venoconstrictor as the parent drug. Like other ergot alkaloids, dihydroergotamine can cause spasm of the coronary and other arteries (dihydroergotamine labels, US Food and Drug Administration, FDA). According to the Spanish rizatriptan SmPC, the effects of rizatriptan with ergotamine and its derivatives add up and raise the risk of coronary artery constriction and hypertensive effects (AEMPS, section 4.5). In a study in 16 healthy men, oral rizatriptan with parenteral ergotamine caused no additional vasospasm, but the same SmPC states that such an effect is theoretically possible (AEMPS, section 4.4). The documents give no data on either drug changing the levels of the other.

Symptoms

Rizatriptan can cause palpitations, raised blood pressure and transient chest tightness and pain, sometimes intense and spreading to the throat. Agonists of 5-HT1B/1D receptors have been associated with coronary artery spasm and, rarely, with myocardial ischaemia and infarction (rizatriptan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.4 and 4.8). Life-threatening ventricular tachycardia and ventricular fibrillation have been reported within a few hours of 5-HT1 agonists, and on rare occasions hypertensive crisis with acute impairment of organ systems. Spasm of other arteries causes ischaemia of the limbs and bowel, with abdominal pain and bloody diarrhoea (rizatriptan label, US Food and Drug Administration, FDA, sections 5.2, 5.5 and 5.8). Dihydroergotamine can cause myocardial infarction, life-threatening arrhythmias, muscle pain, numbness, coldness, pallor and bluish discolouration of the fingers and toes. In people with poor circulation, persistent vasospasm can lead to gangrene or death (dihydroergotamine labels, FDA).

Management

The combination is contraindicated. The Spanish rizatriptan summary of product characteristics (SmPC) contraindicates rizatriptan with ergotamine and ergotamine derivatives (rizatriptan SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5), and its warnings section lists dihydroergotamine among ergotamine medicines (AEMPS, section 4.4). Dihydroergotamine is not in the Spanish medicines register. The US rizatriptan label names dihydroergotamine and contraindicates its use within 24 hours (rizatriptan label, US Food and Drug Administration, FDA, sections 4 and 7.2). The dihydroergotamine labels contraindicate dihydroergotamine in patients who have taken triptans in the previous 24 hours and name rizatriptan among them (dihydroergotamine labels, FDA). The US labels say to keep at least 24 hours between the two drugs, in either order (FDA). The Spanish rizatriptan SmPC recommends waiting at least 6 hours after rizatriptan before dihydroergotamine, and at least 24 hours must pass after an ergotamine-containing product before rizatriptan (AEMPS, section 4.4). If chest pain and tightness suggest cardiac ischaemia, withhold further rizatriptan doses and assess the patient (rizatriptan SmPC, AEMPS, section 4.4). Stop rizatriptan if arrhythmias occur (rizatriptan label, FDA, section 5.2). Stop dihydroergotamine at once if signs of vasoconstriction appear (dihydroergotamine labels, FDA), and rule out vasospasm before the next rizatriptan dose (rizatriptan label, FDA, section 5.5). Rizatriptan is contraindicated in moderately severe or severe hypertension and in untreated mild hypertension (AEMPS, section 4.3), and dihydroergotamine in uncontrolled hypertension (dihydroergotamine labels, FDA). Taking acute migraine drugs, including triptans and ergot drugs, on 10 or more days a month can make headaches more frequent, and the overused drugs may then need to be withdrawn (rizatriptan and dihydroergotamine labels, FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dihydroergotamine

Other interactions with Rizatriptan